fda tirzepatide obesity Approves for Obstructive Sleep Apnea in FDA grants fast track designation

Because established relationships exist between degree of weight loss and cardiovascular event reduction, the greater weight loss with dual agonism raises intriguing hypotheses for greater cardiovascular protection, which could profoundly influence treatment guidelines and coverage policies

Weight loss is a particularly important therapeutic effect, given the strong association between obesity and cardiovascular risk

Somatic mutation rates scale with lifespan across mammals

Semaglutide GLP-1 (Wegovy): Semaglutide GLP-1 is available as a weekly injectable option that many patients find convenient

That means some patients are now paying more, making treatment harder to afford

Among AOMs, prescribing increased slightly in December 2024 compared to September 2024 (+6.98%)